Partnering with Odyssey Therapeutics
Dimension is thrilled to lead the Series D financing of Odyssey Therapeutics, an oversubscribed $213M round alongside other premier investors. Odyssey is at the forefront of developing breakthrough medicines in immunology, uniquely combining deep biological insight with cutting-edge small molecule design capabilities. The company is led by one of the most accomplished teams in biotech and is building the foundation for a new generation of blockbuster drugs.
Immunology remains one of the largest and fastest-growing therapeutic categories, with global sales projected to exceed $200B by 2030. Yet, despite decades of innovation, many patients with autoimmune and inflammatory diseases face limited or incomplete treatment options. Odyssey’s approach — rooted in next-generation target biology and precision drug design — has the potential to deliver highly differentiated therapies that set new standards of efficacy and safety in a space historically dominated by biologics.
Drug development today is shaped by regulatory change, capital constraints and heightened global competition, demanding both scientific novelty and executional speed from biotechs. Odyssey is well-positioned to thrive in this environment. Under the leadership of Gary Glick, the team has assembled a world-class group of scientists with deep expertise in immunology and disease biology. This has enabled the company to build a differentiated pipeline of assets addressing some of the most sought-after targets in the industry. The team has also deeply delved into these targets to arrive at truly unique insights in target biology and underlying mechanisms to address.
Odyssey pairs this unique approach to target and indication selection with a full-stack small molecule design platform. The company has taken a build-and-buy approach to platform development, assembling a comprehensive toolkit that includes generative chemistry, molecular dynamics, natural product screening, and covalent chemistry. In just four years, this integrated engine has enabled Odyssey to build out one of the most robust pipelines in platform biotech that we have come across. The productivity of the platform has resulted in a deep bench of wholly-owned assets, with several of the top priority programs already progressing into clinical development.
With this new round of capital, Odyssey is poised to advance multiple programs through human proof-of-concept over the next several years. Clinical success, combined with platform-driven productivity and the leadership of an exceptional team, positions Odyssey to deliver transformational outcomes in biotech beyond the success of a single program. Dimension is proud to partner with Gary and the Odyssey team to build a generational company. We believe Odyssey’s success will not only reshape treatment for millions of patients with immune-mediated diseases, but also serve as a model for how platform biotech can scale into durable, product-driven companies.
